University of Genova

Advancements in Breast Cancer Research Unveiled at SABCS 2024

5 months ago

• The PATINA trial suggests palbociclib with anti-HER2 and endocrine therapy may become a new standard for HR+, HER2+ metastatic breast cancer. • COMET trial indicates active monitoring is comparable to surgery for low-risk DCIS, offering a potential alternative management option. • OlympiA trial's long-term results reinforce olaparib's role in preventing recurrence and highlight the importance of BRCA testing for early-stage breast cancer.

ESMO 2024: New Leadership and Groundbreaking Developments in Oncology Research and Patient Care

8 months ago

• ESMO President Prof Andres Cervantes highlights the organization's evolution into a comprehensive support network for oncologists, announcing new initiatives including AI & Digital Oncology Congress 2025. • Significant advances in oncofertility research reveal pregnancy after breast cancer is feasible, leading to new fertility preservation laws and guidelines for cancer patients. • Whole Genome Sequencing emerges as a transformative tool in personalized cancer care, with Prof Serena Nik-Zainal demonstrating its potential for identifying unique mutational signatures in individual tumors.

Long-term Benefits of Dose-dense Adjuvant Chemotherapy in Early Breast Cancer Patients

5 years ago

A study with a median follow-up of 15.8 years suggests that dose-dense (DD) chemotherapy may offer long-term benefits for high-risk early breast cancer patients, particularly those with hormone receptor-negative and HER2-positive tumors. The MIG-1 trial compared the efficacy and safety of DD versus standard-interval FEC chemotherapy, showing a trend towards improved outcomes with the DD approach.